--- title: "Ventyx Biosciences directors and officers swapped under merger; Anderson, Haug, Davis join board" type: "News" locale: "en" url: "https://longbridge.com/en/news/277795676.md" description: "Ventyx Biosciences underwent a significant board and officer restructuring following a merger agreement. Six directors and five officers resigned, while new directors and officers from the Merger Sub were appointed. The changes were effective immediately as per the merger agreement, with various individuals taking on new roles, including Christopher Anderson, Jonathan R. Haug, and Sherry D. Davis among others. The specific reasons for the changes were in accordance with the merger agreement, and details about the individuals' backgrounds were not disclosed." datetime: "2026-03-04T14:23:01.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/277795676.md) - [en](https://longbridge.com/en/news/277795676.md) - [zh-HK](https://longbridge.com/zh-HK/news/277795676.md) generator: "portal-rs" --- # Ventyx Biosciences directors and officers swapped under merger; Anderson, Haug, Davis join board **Ventyx Biosciences saw a board and officer overhaul under the Merger Agreement: six directors and five officers resigned and directors and officers from Merger Sub assumed roles effective at the Effective Time.** Individual Onaiza Cadoret-Manier Sheila Gujrathi Allison Hulme Raju Mohan Somu Subramaniam William White Christopher Anderson Jonathan R. Haug Sherry D. Davis Mark Forman Roy Gonzales Matthew Moore John Nuss Steffanie Lim-Ho Jonathan Groff Katie Lodato Role Director Director Director Director; Officer Director Director Director; Secretary; Officer Director; President; Officer Director Officer Officer Officer Officer Treasurer; Officer Assistant Secretary; Officer Assistant Treasurer; Officer Type of Change Resigned Resigned Resigned Resigned Resigned Resigned Appointed Appointed Appointed Resigned Resigned Resigned Resigned Appointed Appointed Appointed Effective Date Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Effective Time Reason In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement In accordance with Merger Agreement Replacement Info Directors from Merger Sub became directors Directors from Merger Sub became directors Directors from Merger Sub became directors Officers from Merger Sub became officers Directors from Merger Sub became directors Directors from Merger Sub became directors N/A (became director; also Secretary) N/A (became director; also President) N/A (became director) Officers from Merger Sub became officers Officers from Merger Sub became officers Officers from Merger Sub became officers Officers from Merger Sub became officers N/A (became Treasurer) N/A (became Assistant Secretary) N/A (became Assistant Treasurer) Background Details Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Previously a director of Merger Sub (also became Secretary) Previously a director of Merger Sub (also became President) Previously a director of Merger Sub Not disclosed Not disclosed Not disclosed Not disclosed Previously officer of Merger Sub (became Treasurer) Previously officer of Merger Sub (became Assistant Secretary) Previously officer of Merger Sub (became Assistant Treasurer) Board/Committee Role Changes Ceased to be member of any committee Ceased to be member of any committee Ceased to be member of any committee Ceased to be member of any committee Ceased to be member of any committee Ceased to be member of any committee Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Not disclosed Original SEC Filing: Ventyx Biosciences, Inc. \[ VTYX \] - 8-K - Mar. 04, 2026 ### Related Stocks - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [VHT.US](https://longbridge.com/en/quote/VHT.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [IHE.US](https://longbridge.com/en/quote/IHE.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [VTYX.US](https://longbridge.com/en/quote/VTYX.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) ## Related News & Research - [Guotai Asset Management sees liquidity boost driving China biotech, innovation drug shares higher](https://longbridge.com/en/news/296448906.md) - [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md) - [SBIO: U.S. Programmatic and EMEA drove 49% of Q2 sales, with margins rising to 61% and profitability expected in H2 2026](https://longbridge.com/en/news/296517769.md) - [LIVE MARKETS-BofA clients flock to tech stocks](https://longbridge.com/en/news/296383193.md) - [U.S. kindergarten vaccine coverage falls, CDC says](https://longbridge.com/en/news/296136711.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**